Register now!
Login
OCTOBER 9-10, 2025
Professional HUB Hannover Medical Park
Hannover, Germany
Scientific Program | Delta Cure - 4th International Meeting |...
On this page you will find the Scientific Program of the Delta...
Scientific Program
| WHO Symposium Chair: Funmi Lesi, (Geneva, CH) | |
| 11.00-11.15 | Recent published literature on HDV epidemiology Alexander Stockdale (Liverpool, UK) |
| 11.15-12.15 | Update on HDV epidemiology in different regions worldwide Ijeoma Ifeorah, Nsukka (NG); Saed Sadiq Hamid, Karachi (PK); Asegir Johannessen, Tønsberg (NO); Thor Dantas, Acre (BR);
Tatyana Kushner, New York (USA); Sabela Lens, Barcelona (ES); Erkin Musabaev, Tashkent (UZ); Angela Peltec, Chișinău (MD); Duger Davaadorj, Mongolia |
| 12.15-12.30 | Roundtable discussion |
| 12.30-13.15 | Light lunch |
| Opening Session | |
| 13.15-13.45 | Welcome by the Chairs and commemoration and honor of Michael Manns Heiner Wedemeyer and Pietro Lampertico |
| SESSION 1 | Pathophysiology: Virology and Immunology Chairs: Lena Allweiss and Stephan Urban |
| 13.45-13.55 | What’s new in HDV virology and immunology? Eloi Verrier |
| 14.00-14.10 | Preclinical models for HDV – from organoids to humanized mice Lena Allweiss |
| 14.15-14.25 | Oral abstract presentation 1 (Poster No. 9)Variable expression of HBs isoforms and HDV antigens in the chronically infected human liver uncovers spatially segregated niches that may limit the impact of HBV-specific therapies - James Lok |
| 14.25-14.35 | Oral abstract presentation 2 (Poster No. 18)Deconvoluting the spatial immune landscape in the HDV/HBV coinfected human liver at single-cell resolution - Shirin Nkongolo |
| 14.35-14.50 | Poster summaries and discussion |
| 14.50-15.15 | Panel discussion: Unmet needs in translational HDV research Arnaud Carpentier, Julie Lucifora, Joachim Lupberger, Christoph Neumann-Haefelin |
| 15.15-16.15 |  Coffee break and DZIF Poster Session No. 1 with guided Poster Tour Helenie Kefalakes and Maria Paola Anolli |
| SESSION 2 | Diagnostic and Natural History Chairs : Maria Buti and Milan Sonneveld |
| 16.15-16.25 | What’s new in HDV natural history? Ivana Carey |
| 16.30-16.40 | What’s new in HDV diagnostics? Marc Luetgehetmann |
| 16.45-16.55 | Role of HBV biomarkers in HDV Valentina Svicher |
| 17.00-17.10 | Oral abstract presentation 3 (Poster No. 33)Understanding the barriers to scaling up hepatitis delta responses - findings from a global survey - Cynthia Pokuah |
| 17.10-17.20 | Oral abstract presentation 4 (Poster No. 31)Risk of liver-related events associated with metabolic comorbidities among individuals with hepatitis delta infection - Laura Telep |
| 17.20-17.35 | Poster summaries and discussion |
| 17.35-17.50 | Break |
| 17.50-18.40 | Presentation of the Delta Cure Awardee 2025: Pei-jer Chen Distinguished Lecture: Understanding HDV replication - insights from a 35 year journey Pej-Jer Chen |
| 20.00 | Networking Dinner |
| SESSION 3 | Current treatment options Chairs: Zaigham Abbas and Cihan Yurdaydin |
| 08.30-08.40 | BLV Real-World data Elisabetta Degasperi |
| 08.40-08.55 | BLV: when to stop? Lessons learned from clinical trials Soo Aleman |
| 09.00-09.10 | Oral abstract presentation 5 (Poster No. 71)Modeling suggests that 2 mg/day bulevirtide monotherapy efficacy is suboptimal in most HDV-infected patients with compensated cirrhosis and CSPH - Harel Dahari |
| 09.10-09.20 | Oral abstract presentation 6 (Poster No. 64)Response-guided bulevirtide treatment: Long-term outcomes observed in the nationwide Austrian hepatitis D cohort study - Marlene Hintersteininger |
| 09.20-09.30 | Oral abstract presentation 7 (Poster No. 53)Bulevirtide—more than an entry inhibitor? - Eberhard Hildt |
| 09.30-09.45 | Poster summaries and discussion |
| 09.45-11.00 | Coffee break and DZIF Poster Session No. 2 with guided Poster Tour Elisabetta Degasperi and Lisa Sandmann |
| SESSION 4 | Drugs in development Chairs: Nancy Reau and Thomas Berg |
| 11.00-11.10 | What have we learned from lonafarnib and PEG-lambda trials? Ohad Etzion |
| 11.15-11.25 | Anti-HBs monotherapy for HDV infection Kosh Agarwal |
| 11.30-11.40 | Anti-HBs and siRNAs: Update 2025 Tarik Asselah |
| 11.45-11.55 | Oral abstract presentation 8 (Poster No. 47)Antisense oligonucleotide-based strategy to target hepatitis delta virus infections - Julie Lucifora |
| 11.55-12.05 | Oral abstract presentation 9 (Poster No. 46)IB-001 is a Partial Agonist of the Type 1 Interferon Pathway that Exhibits Potent Antiviral Activity against HBV and HDV with the Potential for an Improved Safety Profile - Carey Hwang |
| 12.05-12.15 | Novel TLRs, NAPs, Vaccines, other entry inhibitors Massimo Levrero |
| 12.20-12.30 | New developments in HBV drug development including genome and epigenomic editing – relevance for HDV? Barbara Testoni, Lyon |
| 12.35-12.50 | Discussion: Promising directions in drug development Ohad Etzion, Kosh Agarwal, Tarik Asselah, Barbara Testoni, N.N. |
| 12.50-13.45 | Light Lunch |
| SESSION 5 | The future and unmet needs of Hepatitis Delta Chairs: Heiner Wedemeyer and Pietro LamperticoCo-Chair: Maura Dandri |
| 13.45-13.55 | Oral presentation: Novel genetic immunotherapies for prevention and treatment of HDV InfectionsMatti Sällberg |
| 13.55-14.05 | New EASL HBV Guidelines: Implications for Hepatitis D Markus Cornberg |
| 14.10-14.20 | Lessons learned from interferon use in HCV and HBV Jordan Feld |
| 14.25-15.15 | Roundtable discussion with Faculty representatives, patient representatives, representatives from diagnostics and health industry, and the Delta Cure audience for Science a.o. Markus Cornberg, Jordan Feld, Robert Gish, Jeffrey Glenn, Massimo Levrero, Rafael Esteban |
| 15.15-15.30 | Closing remarks and farewell Heiner Wedemeyer and Pietro Lampertico |
